Shionogi initiates phase I trial in Japan of 3CL protease inhibitor S-217622 for COVID-19 July 26, 2021
Addition of CF-296 to SOC leads to enhanced antibacterial activity against MSSA and MRSA isolates July 22, 2021
RSS